Investors

Investor materials

Programmable Bio is building LabOS — the agentic operating system for distributed biology, anchored on Apollo Hospitals' clinical substrate and expanding to APAC via Singapore BioHelix.

Investment highlights

  • Category-defining window — autonomous labs commercial in 2026; no indigenous India platform at scale
  • Apollo moat — pan-India EHR + biobank substrate; 3–5 year replication barrier
  • LabOS platform — five-agent mesh, provenance-signed experimental graph, LIMS-native wedge
  • Dual revenue engine — SaaS (LabOS/OmicsCloud) + milestone discovery sprints (IVD, PV)
  • APAC corridor — Singapore BioHelix node + MiRXES i4.0 manufacturing partnership
  • Software margins — partner CRO execution in Phase 1; no $50M+ FAL CapEx

Public blueprint at programmablebio.tech. Deck access is for qualified investors and strategic partners only.

Request pitch deck

Financial projections are indicative and scenario-based. Nothing on this site constitutes an offer of securities. By submitting, you agree to be contacted regarding Programmable Bio. We do not share your information with third parties.